Value-based pricing will not harm industry, says NICE chief
pharmafile | February 18, 2011 | News story | Sales and Marketing | Health Select Committee, Health and Social Care Bill, NHS reform, NICE, Sir Andrew Dillon, value-based pricing
NICE’s chief executive Sir Andrew Dillon says he believes plans to introduce value-based pricing of medicines will not have a negative effect on the pharma industry.
Dillon was appearing before the committee of MPs charged with scrutinising the government’s Health and Social Care Bill, which encompasses mammoth reform of the health service as well as the pricing of medicines.
When asked whether or not value-based pricing (VBP) would have a negative impact on the UK pharma industry, Sir Andrew said: “It is likely to be on a range of neutral to positive.”
He added: “It can be positive if it achieves the aim of the government’s proposals – achieves our ambition of providing a clearer signal to the pharmaceutical industry about the sorts of products and the sorts of disease areas that we really want the industry to concentrate on.”
Dillon added that the aims of the VBP proposal were ‘entirely laudable’: “To fix a price of a drug that reflects accurately the additional benefits it brings over current standard practice; and the plan calls for more transparency and more clarity in what the NHS regards as value for new treatments, so that there is greater predictability in the process for everybody.”
He reassured the cross-bench committee of MPs that NICE would continue its clinical and cost effectiveness appraisals, but would no longer issue final recommendations direct to the NHS.
“It will still be possible for prescribers and the public to see just where a new treatment really scores in terms of additional benefit compared with what is available at the moment.
“We need to wait and see what the outcome of the consultation is to see the final arrangements and then to make an assessment of their ultimate impact,” he added.
Andrew McConaghie
Related Content
Combination treatments: Takeda’s Implementation Framework and the broader landscape
Pharmafile talks to Emma Roffe, Oncology Country Head (UK & Ireland) about the combination treatment …
NICE recommends Pfizer’s new once-weekly treatment for haemophilia B on NHS
Walton Oaks, 21st May 2025 – Pfizer Ltd announced today that the National Institute for Health and Care …
Dual immunotherapy for bowel cancer now available under NHS
Dual immunotherapy, a combination of Opdivo (nivolumab) and Yervoy (ipilimumab), has been granted extension in …
